Opaleye Management as of Sept. 30, 2019
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the September 2019 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Codexis (CDXS) | 6.7 | $19M | 1.4M | 13.71 | |
Stereotaxis (STXS) | 5.2 | $14M | 4.1M | 3.51 | |
Epizyme | 5.1 | $14M | 1.4M | 10.32 | |
Imprimis Pharmaceuticals | 4.8 | $13M | 2.4M | 5.62 | |
Eidos Therapeutics | 4.0 | $11M | 306k | 35.97 | |
Turning Point Therapeutics I | 3.9 | $11M | 288k | 37.60 | |
Amarin Corporation (AMRN) | 3.5 | $9.8M | 645k | 15.16 | |
Odonate Therapeutics Ord | 3.3 | $9.1M | 350k | 26.03 | |
Ocular Therapeutix (OCUL) | 3.0 | $8.4M | 2.8M | 3.04 | |
Axogen (AXGN) | 3.0 | $8.4M | 700k | 11.97 | |
Uniqure Nv (QURE) | 2.9 | $8.1M | 205k | 39.36 | |
Cara Therapeutics (CARA) | 2.9 | $8.0M | 440k | 18.28 | |
Audentes Therapeutics | 2.9 | $8.0M | 285k | 28.09 | |
Deciphera Pharmaceuticals (DCPH) | 2.8 | $7.8M | 230k | 33.94 | |
Blueprint Medicines (BPMC) | 2.8 | $7.7M | 105k | 73.47 | |
Cytokinetics | 2.7 | $7.4M | 650k | 11.38 | |
Xoma Corp Del (XOMA) | 2.7 | $7.4M | 375k | 19.71 | |
Eton Pharmaceuticals (ETON) | 2.7 | $7.4M | 1.2M | 6.32 | |
ACADIA Pharmaceuticals (ACAD) | 2.6 | $7.2M | 200k | 35.99 | |
Cerecor | 2.6 | $7.2M | 2.2M | 3.29 | |
Biohaven Pharmaceutical Holding | 2.4 | $6.7M | 160k | 41.72 | |
Ptc Therapeutics I (PTCT) | 2.3 | $6.4M | 190k | 33.82 | |
Tricida | 2.2 | $6.0M | 195k | 30.87 | |
Avenue Therapeutics | 2.0 | $5.7M | 953k | 5.96 | |
Fibrogen (FGEN) | 2.0 | $5.5M | 150k | 36.98 | |
Shockwave Med (SWAV) | 1.7 | $4.8M | 160k | 29.93 | |
Zymeworks | 1.5 | $4.2M | 170k | 24.80 | |
Quanterix Ord (QTRX) | 1.5 | $4.1M | 185k | 21.96 | |
Magenta Therapeutics | 1.4 | $4.0M | 385k | 10.26 | |
Tg Therapeutics (TGTX) | 1.2 | $3.4M | 613k | 5.61 | |
Ra Pharmaceuticals | 1.2 | $3.4M | 142k | 23.65 | |
Crinetics Pharmaceuticals In (CRNX) | 1.1 | $3.1M | 207k | 15.04 | |
Synthorx | 1.1 | $2.9M | 180k | 16.27 | |
Neoleukin Therapeutics | 1.0 | $2.8M | 995k | 2.85 | |
Forty Seven | 1.0 | $2.7M | 425k | 6.42 | |
Nextcure (NXTC) | 0.9 | $2.6M | 85k | 30.85 | |
Fortress Biotech | 0.8 | $2.3M | 1.7M | 1.41 | |
Radius Health | 0.7 | $1.9M | 75k | 25.75 | |
Aptose Biosciences | 0.5 | $1.5M | 720k | 2.08 | |
Flexion Therapeutics | 0.5 | $1.4M | 105k | 13.70 | |
Edap Tms (EDAP) | 0.5 | $1.3M | 300k | 4.49 | |
Chemocentryx | 0.5 | $1.4M | 200k | 6.78 | |
Intra Cellular Therapies (ITCI) | 0.5 | $1.3M | 170k | 7.47 | |
Strongbridge Bioph shs usd | 0.4 | $1.2M | 490k | 2.39 | |
Cymabay Therapeutics | 0.3 | $717k | 140k | 5.12 | |
Vermillion | 0.2 | $658k | 1.3M | 0.52 | |
Assembly Biosciences | 0.2 | $492k | 50k | 9.84 | |
Biolinerx Ltd-spons | 0.0 | $44k | 17k | 2.64 | |
Proteon Therapeutics | 0.0 | $14k | 54k | 0.26 |